ClinicalTrials.gg
RecruitingNCT05501704Updated Aug 24, 2026

ETHAN - ET for Male BC

A Phase 2 interventional study of Tamoxifen and Anastrozole in Male Breast Cancer, Hormone Receptor-positive Breast Cancer and Hormone Receptor Negative Breast Carcinoma, sponsored by Jose Pablo Leone. Recruiting at 9 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Jose Pablo Leone · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 234 studies in Breast Neoplasms, Male with a site in United States — 2 open to participants now, 9 under way, 4 of them phase 3. Breast Neoplasms, Male · United States.

Planned enrollment
51st of 207
60 · median 34
Started
2023
with 1 other
Phase 2
88 of 234
1 open now
Registered
231st of 234
by date

Among the 234 studies in Breast Neoplasms, Male with a site in United States, this one is the 51st largest by planned enrollment of the 207 interventional ones that give a count, is one of 2 that started in 2023, is one of 88 in phase 2, and was the 231st registered.

Breast Neoplasms, Male

286 studies on the registry are indexed under Breast Neoplasms, Male; 5 are open to participants now.

Browse Breast Neoplasms, Male studies →

Open to participants now

2 of the 234 studies in Breast Neoplasms, Male with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Breast Neoplasms, Male studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 234 studies in Breast Neoplasms, Male with a site in United States, or all of them as a file.
02

Study summary

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer.

The drugs used in this study are:

  • Tamoxifen
  • Anastrozole
  • Degarelix
  • Abemaciclib
Read the detailed description

This is an open-label, multicenter, randomized trial for men with stage I-III hormone receptor-positive (HR+)/HER2-negative breast cancer. The trial will have two phases: A 3-week window phase containing endocrine therapy followed by a 4-month treatment phase where participants are treated with one of four endocrine therapy treatment combinations.

Tamoxifen is the standard of care for the treatment of breast cancer in men. Anastrozole is a standard treatment in women with breast cancer and works more effectively than tamoxifen. This study hopes to learn if anastrozole may also be effective in men. Given that gonadal suppression and CDK 4/6 inhibitors have both improved treatment in women with breast cancer, the study hopes to learn how the addition of Degarelix (gonadal suppression) and Abemaciclib (CDK 4/6 inhibitors) work in comparison to standard of care tamoxifen.

The research study procedures include screening for eligibility and study treatment including laboratory evaluations and quality of life questionnaires.

After completion of treatment, participants will be followed for up to 10 years

It is expected that about 60 men will take part in this research study.

Eli Lilly, a pharmaceutical company, is supporting this research study by providing one of the study drugs. This study is also being supported by Johns Hopkins University on behalf of the Translational Breast Cancer Research Consortium (TBCRC).

03

Conditions studied

  • Male Breast Cancer
  • Hormone Receptor-positive Breast Cancer
  • Hormone Receptor Negative Breast Carcinoma

Keywords

  • Male Breast Cancer
  • Hormone Receptor-positive Breast Cancer
  • Hormone Receptor Negative Breast Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary nodes.
  • Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112).
  • Breast cancer must be hormone receptor-positive and -negative according to definition below assessed by local pathology.

    • Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR]) by IHC. ER and PR assays are considered positive if there are > 1% positive tumor nuclei in the samples.
    • HER2-negative is defined per the current American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline (113).
  • Patients with multifocal or multicentric disease are eligible if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.
  • Bilateral breast cancers are allowed if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative.
  • Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible.
  • performance status ≤ 2.
  • Required laboratory values demonstrating adequate organ function:

    • ≥ 1000/mm3
    • ≥ 8 g/dl
    • ≥ 50,000/mm3
    • Serum creatinine ≤ 3.0 x (institutional)
    • Total ≤ 2.0 x ULN (institutional).
    • and ALT ≤ 5.0 x ULN (institutional)
  • Men with partners of must be willing to use one highly effective form of non-hormonal or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 6 months after the last dose of study treatment.
  • Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires.
  • Willing and able to sign .
  • Willing to undergo breast after completion of window phase.
  • Patient is able to swallow oral medications.

Exclusion criteria

Exclusion Criteria:

  • Prior endocrine therapy, chemotherapy, radiation therapy, or therapy for the current breast cancer diagnosis.
  • Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other within the past 12 months.
  • Diagnosis of inflammatory breast cancer (T4d).
  • Other concurrent serious diseases that may interfere with planned treatment, including severe cardiac disease, congestive heart failure (CHF) of (NYHA) Class III or higher, severe pulmonary conditions/illness, uncontrolled infections.
  • The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated \<30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
  • The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known positivity or with known active or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.
  • The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Window Phase Arm A: Tamoxifen

    Participants will be randomly assigned to receive Tamoxifen 1x daily for 3 weeks (21days).

    Drug: Tamoxifen

  • Experimental
    Window Phase Arm B: Anastrozole

    Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days).

    Drug: Anastrozole

  • Experimental
    Window Phase Arm C: Anastrozole + Degarelix

    Participants will be randomly assigned to receive Anastrozole 1x daily for 3 weeks (21days) and Degarelix on day 1 only.

    Drug: Anastrozole · Drug: Degarelix

  • Experimental
    Neoadjuvant Phase Arm D: Tamoxifen

    Participants will be randomly assigned to receive Tamoxifen 1x daily for 4 cycles (4 months); each study cycle is 28 days.

    Drug: Tamoxifen

  • Experimental
    Neoadjuvant Phase Arm E: Tamoxifen + Abemaciclib

    Participants will be randomly assigned to receive Tamoxifen 1x daily and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.

    Drug: Tamoxifen · Drug: Abemaciclib

  • Experimental
    Neoadjuvant Phase Arm F: Anastrozole and Degarelix

    Participants will be randomly assigned to receive Anastrozole 1x daily and Degarelix on day 1 of each cycle for 4 cycles (4 months); each study cycle is 28 days.

    Drug: Anastrozole · Drug: Degarelix

  • Experimental
    Neoadjuvant Phase Arm G: Anastrozole + Degarelix + Abemaciclib

    Participants will be randomly assigned to receive Anastrozole 1x daily, Degarelix on day 1 of each cycle and Abemaciclib 2x daily for 4 cycles (4 months); each study cycle is 28 days.

    Drug: Anastrozole · Drug: Degarelix · Drug: Abemaciclib

Interventions

  • Taken orally

    Also known as: Nolvadex, Soltamox

  • Taken orally

    Also known as: Arimidex

  • Subcutaneous (under the skin) injection

  • Taken orally

    Also known as: Verzenio

06

What researchers measure

Primary outcomes

  1. Change in Ki-67

    Ki-67 will be evaluated by ImmunoHistoChemistry (IHC) following consensus recommendations using imaging analysis methods.

    Time frame: At the end of the 3-week window period.

  2. RCB index

    RCB will be determined using data from each participating institution pathology department, and will be reviewed by the study team pathologist.

    Time frame: At time of surgery.

Secondary outcomes

  1. Changes in estradiol levels

    To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by estradiol levels at baseline and at the end of the three-week window period

    Time frame: Baseline and at the end of the three-week window period

  2. Changes in testosterone levels

    To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by testosterone levels at baseline and at the end of the three-week window period

    Time frame: Baseline and at the end of the three-week window period

  3. Preoperative Endocrine Prognostic Index (PEPI) score

    To evaluate the comparative efficacy of the experimental treatments as measured by PEPI score at surgery.

    Time frame: At time of surgery

Other outcomes

  1. Grade 3 or Higher Treatment-Related Toxicity Rate

    All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation.

    Time frame: Up to 6 months

  2. Trial enrollment

    We will evaluate how many patients we are able to enroll to this trial in a period of 3 years

    Time frame: 3 years

  3. Trial completion

    We will evaluate how many of the enrolled participants successfully complete the study protocol

    Time frame: 3 years

  4. EORTC QLC-C30 questionnaire

    Patient-reported outcomes (PROs) measures will be conducted using the EORTC QLC-C30 questionnaire.

    Time frame: Up to 6 months

  5. Adapted EORTC BR23 questionnaire

    Patient-reported outcomes (PROs) measures will be conducted using the EORTC BR23, adapted by replacing female-specific items with male-specific sexual activity/function items from PR25 (Appendix D of protocol) questionnaire.

    Time frame: Up to 6 months

07

Study locations

9 of 9 sites recruiting
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
    Recruiting
    • Clinical Trials Office Breast Cancer · Contact202-444-2223
    • Elaine Walsh, MD · Principal investigator
  • Mayo Clinical Hospital Florida
    Jacksonville, Florida 32224, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
    Recruiting
    • Jose Pablo Leone, MD · Contact617-789-2903
    • Jose Pablo Leone, MD · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Cancer Trials Referral Office · Contact855-776-0015
    • Kathryn Ruddy, MD · Principal investigator
  • UNC Lineberger Comprehensive Cancer Center
    Chapel Hill, North Carolina 27599, United States
    Recruiting
  • University of Pennsylvania, Abramson Cancer Center
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University of Pittsburgh Cancer Institute
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Rometa Kerney · Contactpollardrr@upmc.edu · (412) 641-5430
    • Priscilla McAuliffe, MD · Principal investigator
  • Vanderbilt Cancer Center
    Nashville, Tennessee 37232, United States
    Recruiting
  • M. D. Anderson Cancer Center at University of Texas
    Houston, Texas 77030-4009, United States
    Recruiting
    • Clinical Trials Office - M. D. Anderson Cancer Center at the U · Contact713-792-3245
    • Jasmine Sukumar, M.D · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Apr 2027, 41 months after the start.

Of 20 phase 2 interventional studies under Breast Neoplasms, Male, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 75. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2022
First posted
Aug 15, 2022
StartActual
Oct 11, 2023
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2036
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501704
Lead sponsor
Jose Pablo Leone
Collaborators
Eli Lilly and Company, Translational Breast Cancer Research Consortium
Responsible party
Jose Pablo Leone (Principal Investigator, Dana-Farber Cancer Institute) — Sponsor-investigator
First posted
Aug 15, 2022
Start date
Oct 11, 2023
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2036 (estimated)
Last update
Aug 24, 2026

Study contacts

Jose Pablo Leone, MD
Contact
josep_leone@dfci.harvard.edu
617-789-2903
Jose Pablo Leone, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tamoxifen · Anastrozole · Degarelix · Abemaciclib

Start the discussion